本帖最后由 老马 于 2012-1-13 21:20 编辑 8 u/ Z4 T3 \* \, F o4 j
' H) I" [+ E; N; Y0 R
爱必妥和阿瓦斯丁的比较
: U9 I% h+ Q; L3 S- f' v
5 G4 e3 ^$ J; T( s- F6 R
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/" N- R# a: ?: Y' `- Q. s! t M5 `1 M
! j. L# B% M, R, [6 _
' Y# M5 J& U# Q0 i, ?4 Bhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
5 O5 P; @5 X0 O9 M2 w" |( e==================================================
0 W9 ~) \, k+ |5 C" O. IOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, }' p! Z9 D2 H2 a5 R; K* \Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
% Y+ h. \7 n7 O4 x; iResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
- K1 m& w/ s# o& t3 P
|